1. Home
  2. SOS vs BGLC Comparison

SOS vs BGLC Comparison

Compare SOS & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOS Limited

SOS

SOS Limited

N/A

Current Price

$1.62

Market Cap

10.7M

Sector

Finance

ML Signal

N/A

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

N/A

Current Price

$3.34

Market Cap

10.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOS
BGLC
Founded
2004
2017
Country
China
Malaysia
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7M
10.1M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SOS
BGLC
Price
$1.62
$3.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
33.5K
9.1K
Earning Date
09-26-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$260,505,000.00
$9,465,006.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
134.43
2.21
52 Week Low
$1.02
$2.01
52 Week High
$9.62
$15.60

Technical Indicators

Market Signals
Indicator
SOS
BGLC
Relative Strength Index (RSI) 50.91 27.33
Support Level $1.58 $3.69
Resistance Level $1.82 $3.80
Average True Range (ATR) 0.09 0.21
MACD -0.01 -0.06
Stochastic Oscillator 49.97 16.96

Price Performance

Historical Comparison
SOS
BGLC

About SOS SOS Limited

SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Share on Social Networks: